Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Bofanglutide

Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects

Gan & Lee Pharmaceuticals · Phase 3 · Recruiting · Enrollment 420

NCT07150975

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
GZR18 Dose Level 1n/rn/rn/rn/r
GZR18 Dose Level 2n/rn/rn/rn/r
Semaglutide(Wegovy® )2.4 mgn/rn/rn/rn/r

Not shown

  • GZR18 Dose Level 1: endpoint not reported
  • GZR18 Dose Level 2: endpoint not reported
  • Semaglutide(Wegovy® )2.4 mg: endpoint not reported